<DOC>
	<DOCNO>NCT02472353</DOCNO>
	<brief_summary>The goal study determine co-administration metformin doxorubicin breast cancer patient receive neoadjuvant adjuvant therapy reduce number patient develop significant change leave ventricle ejection fraction ( LVEF ) .</brief_summary>
	<brief_title>Use Metformin Reduce Cardiac Toxicity Breast Cancer</brief_title>
	<detailed_description>This randomize , open-label , phase II design pilot study patient breast cancer require neoadjuvant adjuvant chemotherapy . Eligible patient equally randomize either receive metformin plus standard care therapy standard care therapy alone . Patients receive metformin continue drug doxorubicin-containing cycle complete , unless unacceptable toxicity occur patient decides withdraw study . Both arm study undergo echocardiogram contrast baseline , upon completion doxorubicin-containing cycle ( within 28 day completion ) , one-year seven-year time point . Additionally biomarker lab obtain explore correlation change cardiac activity activity metformin . If willing , enrolled patient provide sample whole blood exploratory analysis . Symptoms report study correlate know single nucleotide polymorphism ( SNPs ) find exploratory genomic analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Breast cancer require neoadjuvant adjuvant therapy doxorubicin Complete metabolic panel demonstrate adequate organ function define follow : AST le 2.5 time ULN ; ALt le 2.5 time ULN ; alkaline phosphatase less 2.5 time ULN ; serum creatinine le 1.5 mg/dL ; serum bilirubin less ULN ECOG performance status 0 1 Age great equal 21 year Known diabetes History cardiac arrhythmia symptomatic cardiac disease Currently take antiarrhythmic medication , betablockers , rate control cardiac medication Currently take metformin and/or sulfonylurea Known hypersensitivity intolerance metformin Baseline ejection fraction le 50 % measure echocardiogram Known hypersensitivity contrast use echocardiogram Risk factor associate increase risk metforminassociated lactic acidosis ( e.g . congestive heard failure , history acidosis , habitual intake 3 alcoholic beverage per day ) Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>metformin</keyword>
	<keyword>cardiotoxicity</keyword>
	<keyword>ejection fraction</keyword>
	<keyword>LVEF</keyword>
</DOC>